| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Operating loss | -2,899 | -1,905 | -1,878 | -1,760 |
| Other income, net | 1,078 | 306 | 49 | 43 |
| Loss before income taxes | -1,821 | -1,599 | -1,829 | -1,717 |
| Income tax expense | 0 | 0 | - | - |
| Net loss attributable to common stockholders | -1,821 | -1,599 | -1,829 | -1,717 |
| Foreign currency translation adjustments | -19 | -3 | -18 | -15 |
| Comprehensive loss | -1,840 | -1,602 | -1,847 | -1,732 |
| Basic and diluted (in dollars per share) | -0.02 | -0.02 | -0.02 | -0.02 |
| Basic and diluted (in dollars per share) | -0.02 | -0.02 | -0.02 | -0.02 |
| Weighted-average number of shares used in computing loss per share amounts (in shares) | 90,457,910 | 83,027,117 | 77,633,004 | 76,007,129 |
| Weighted-average number of shares used in computing loss per share amounts (in shares) | 90,457,910 | 83,027,117 | 77,633,004 | 76,007,129 |
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)